At 11.8x earnings and just 9.5x forward earnings, the market is pricing TM like a no-growth cyclical despite a massive $274,486M market cap and positive forward EPS expansion to $17.80. The valuation looks optically cheap, but the PEG Forward of 24 signals that growth relative to price is not compelling, suggesting either distorted growth expectations or structural earnings volatility. The real concern is the Altman Z-Score of 1.7, which places the company in financial stress territory, meaning balance sheet risk is not trivial. This is a statistically cheap stock with balance sheet fragility—more deep value with risk than clean GARP.